Clinical trials: Neoplastic Cells, Circulating
Colorectal Cancer, Non Small Cell Lung Cancer
Circulating DNA to Improve Outcome of Oncology PatiEnt. A Randomized Study
COPE is a biology driven protocol with 2 independent, multicentric, two-arm non-comparative randomized (2:1) phase II trials in 2 distinct populations: colorectal cancer patients and non-small-lung cancer patients.
- Trial name
- COPE (NCT04258137)
- Testing
- Liquid biopsy
- Where
- 6 sites in France
- Volunteers
- 332 people
- Sponsor
- Institut Bergonié
Colorectal Cancer
Cancer Stem Cell Markers and Prognostic Markers in Circulating Tumor Cells
The study will enroll patients with metastatic colorectal cancer receiving chemotherapy. A total of approximately 22 cc of blood will be drawn during various chemotherapy infusions.
- Trial name
- NCT01286883
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Milton S. Hershey Medical Center
Merkel Cell Carcinoma
Identification and Characterization of Circulating Tumor Cells Before and After Treatment (Surgery and Radiotherapy) in a Cohort of Patients Treated for Resectable Stage I-III Merkel Cell Carcinoma
The goal of this prospective observational study is to evaluate the presence of circulating tumoral cells in patients over 18 with a stage I-III resectable Merkel cell carcinoma after the initial therapeutic sequence of surgery…
- Trial name
- MERCCALIBI (NCT06448611)
- Testing
- Blood Test
- Volunteers
- 25 people
- Sponsor
- University Hospital, Montpellier
Cancer, Esophagus Squamous Cell Carcinoma
Multi-Omic Assessment of Squamous Cell Cancers Receiving Systemic Therapy
This is prospective research study which will include patients with recurrent or metastatic squamous cell carcinoma of the head and neck, esophagus and anal canal starting on first-line platinum based chemotherapy or any line of…
- Conditions
- Cancer, Esophagus Squamous Cell Carcinoma, Squamous Cell Carcinoma of the Head and Neck, Anal Canal Squamous Cell Carcinoma
- Trial name
- MASST (NCT03712566)
- Where
- Canada
- Volunteers
- 39 people
- Sponsor
- University Health Network, Toronto
Prostate Cancer
Circulating Tumor Cells and mpMRI for Non-invasive Diagnosis of Prostate Cancer(CMNDPC)
This trial is a prospective, multicentre, diagnostic study. This study aims to evaluation the early diagnostic ability of circulating tumor cells plus multimodal MRI for prostate cancer.
- Trial name
- CMNDPC (NCT05947188)
- Testing
- prostate cancer diagnosis
- Where
- China
- Volunteers
- 808 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Estrogen Receptor Negative, Estrogen Receptor Positive
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast Cancer
The purpose of the study is to evaluate the impact on progression-free survival (PFS) with the combination carboplatin - pembrolizumab in patients with CTC (circulating tumor cells) positive, HER2 negative metastatic breast…
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, Progesterone Receptor Negative
- Trial name
- NCT03213041
- Testing
- Carboplatin, Laboratory Biomarker Analysis, Pembrolizumab
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Northwestern University
Non Small Cell Lung Cancer, Circulating Tumor Cell
WHENII - Early Response Evaluation With FDG-PET/CT and Liquid Biopsy in Patients With NSCLC
Response evaluation with FDG-PET and free circulating DNA in patients with inoperable lung cancer of non small cell type during first treatment with chemotherapy or immunotherapy.
- Conditions
- Non Small Cell Lung Cancer, Circulating Tumor Cell, Circulating Tumor DNA
- Trial name
- WHENII (NCT03481101)
- Testing
- PET/CT
- Where
- 2 sites in Denmark
- Volunteers
- 60 people
- Sponsor
- Copenhagen University Hospital, Rigshospitalet
Circulating Tumor Cells, Pancreatic Adenocarcinoma
Detection of Circulating Tumor Cells for the Diagnostic of Pancreatic Adenocarcinoma.
Histological proof is a crucial and necessary step for appropriate care in oncology. In the case of pancreatic cancer, histological proof from pathological analysis of the surgical specimen is very rare due to the limited number…
- Conditions
- Circulating Tumor Cells, Pancreatic Adenocarcinoma, Circulating Tumor DNA (KRAS), CA 19.9
- Trial name
- CTC-Pancreas (NCT02072616)
- Testing
- Pancreatic adenocarcinoma diagnosis
- Where
- France
- Volunteers
- 101 people
- Sponsor
- University Hospital, Rouen
Pleural Neoplasms, Mesothelioma
The ISET (Isolation by Size of Epithelial Tumor Cells) and the CellSearch Methods in Malignant Pleural Mesothelioma
Malignant pleural mesothelioma (MPM) has a growing incidence and in spite of early diagnostic, their outcome remains dismal. The evolution of MPM is often local with rare distant metastases.
- Conditions
- Pleural Neoplasms, Mesothelioma, Pneumothorax, Parathyroid Neoplasms
- Trial name
- NCT01776385
- Testing
- Blood sampling, Control Group
- Where
- France
- Volunteers
- 9 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Metastatic Colorectal Cancer
Study of Circulating Markers in Serum of Patients Treated for Metastatic Colorectal Cancer
The primary purpose of the study is to confirm the results of previous study about the usefulness of the serum Carcinoembryonic antigen (CEA) kinetic for chemotherapy monitoring in patients with unresectable metastasis of…
- Trial name
- Coca-Colon (NCT01212510)
- Testing
- Blood sampling
- Where
- 4 sites in France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Rouen
Cancer
Analysis of Circulating Tumor Markers in the Blood (ALCINA)
Exploratory study on blood-borne biological markers and their correlation with clinical and pathological characteristics.
- Trial name
- ALCINA (NCT02866149)
- Testing
- Blood sampling, Tumor sampling, Stool sampling
- Where
- 5 sites in France
- Volunteers
- 682 people
- Sponsor
- Institut Curie
Colorectal Neoplasms Malignant, Minimal Residual Disease
Circulating Tumor DNA Based Decision for Adjuvant Treatment in Colon Cancer Stage II-III
This trial has been designed to prove the feasibility of using liquid biopsy detection of minimal residual disease (MRD) to guide the postsurgical clinical management of early colon cancer patients.
- Conditions
- Colorectal Neoplasms Malignant, Minimal Residual Disease, Circulating Tumor Cell
- Trial name
- NCT07821333
- Testing
- FOLFOXIRI, CAPOX
- Where
- 7 sites in Spain
- Volunteers
- 45 people
- Sponsor
- Fundación para la Investigación del Hospital Clínico de Valencia
Prostate Cancer
Pilot Study of PLX3397 in Patients With Advanced Castration-Resistant Prostate Cancer (CRPC)
The main objective of this study is to evaluate the effects of PLX3397 on male subjects with CRPC. Secondary objectives include evaluating the safety and tolerability of PLX3397 and the anti-tumor effects that PLX3397 has on the…
- Trial name
- NCT01499043
- Testing
- PLX3397
- Where
- 2 sites in United States
- Volunteers
- 6 people
- Sponsor
- Daiichi Sankyo
Lung Neoplasms
Multicenter Validation of the Sensitivity of Theranostic ALK Rearrangement Detection by FISH Analysis and Prevalence of Escaping Mutations in Circulating Tumor Cells for the Non-invasive Management of Lung Cancer Patients
Patients eligibility to targeted therapies relies on a molecular test performed on a tumor sample collected by biopsy. This invasive procedure is associated with a relative high risk of morbidity and requires the intervention of…
- Trial name
- STALKLUNG01 (NCT02372448)
- Testing
- ALK analysis on CTCs detected by ISET
- Where
- 11 sites in France
- Volunteers
- 206 people
- Sponsor
- Centre Hospitalier Universitaire de Nice
Circulating Tumor Cell
Circulating Tumor Cell Detection in Hepatocellular Carcinoma
The investigators examined circulating tumor cells (CTC) in the perioperative peripheral blood of hundreds of HCC patients undergoing liver cancer surgery using CellSearch technology between 2013 and 2016.
- Trial name
- NCT05297955
- Where
- China
- Volunteers
- 458 people
- Sponsor
- Tongji Hospital
Carcinoma, Non-Small-Cell Lung, Cell, Circulating Tumor
Dynamic Circulating Tumor Cell (CTC) Changes During the Chemotherapy in NSCLC
Primary endpoint To observe the dynamic changes of CTC during the process of platinum based chemotherapy in advanced NSCLC. To study the relationship between CTC count and clinical outcome of chemotherapy (ORR and PFS).
- Trial name
- POLICE (NCT01740804)
- Where
- China
- Volunteers
- 180 people
- Sponsor
- Guangdong Association of Clinical Trials
Non-small Cell Lung Cancer, Esophageal Cancer
Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers
Patients with resectable solid primary cancers and even limited number of metastases are potentially curable. However, most patients develop recurrences despite surgery.
- Conditions
- Non-small Cell Lung Cancer, Esophageal Cancer, Gastric Cancer, Pancreatic Cancer
- Trial name
- NCT02838836
- Testing
- Study sample collection
- Where
- United States
- Volunteers
- 620 people, healthy volunteers welcome
- Sponsor
- University of Missouri-Columbia
Non-small Cell Lung Cancer (NSCLC)
The Utility of Circulating Tumor Cells as Confirmation of Pathologic Diagnosis in Patients With Suspected Early Stage Non-small Cell Lung Cancer
The primary objective of this study is to determine whether circulating tumor cells (CTCs) can be used as a non-invasive means of confirming pathologic diagnosis in early-stage (Stage I) non-small cell lung cancer (NSCLC).
- Trial name
- NCT02380196
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Abramson Cancer Center at Penn Medicine
Breast Neoplasms
Early Detection of Breast Cancer
The TriNetra™ Breast test is intended for use as a breast cancer screening test that evaluates Circulating Tumor Cells (CTCs) associated with breast cancer.
- Trial name
- NCT06043661
- Where
- United States
- Volunteers
- 700 people, healthy volunteers welcome
- Sponsor
- Datar Cancer Genetics Inc
Prostate Cancer
Cultured Circulating Tumor Cells in Prostate and Other Cancers
The purpose of this study is to evaluate the number of circulating tumor cells (CTC) before and after treatment using an experimental method for detecting CTC, compared to commercial CTC assay results, in patients with prostate…
- Trial name
- NCT02123862
- Where
- United States
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Oscar Goodman, Jr.